BridgeBio Pharma Statistics
Total Valuation
BBIO has a market cap or net worth of $6.96 billion. The enterprise value is $8.01 billion.
Important Dates
The last earnings date was Thursday, February 20, 2025, before market open.
| Earnings Date | Feb 20, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
BBIO has 188.99 million shares outstanding. The number of shares has increased by 14.30% in one year.
| Current Share Class | 188.99M |
| Shares Outstanding | 188.99M |
| Shares Change (YoY) | +14.30% |
| Shares Change (QoQ) | +0.49% |
| Owned by Insiders (%) | 5.15% |
| Owned by Institutions (%) | 66.37% |
| Float | 131.95M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 30.90 |
| Forward PS | 58.33 |
| PB Ratio | -4.78 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 36.11 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 5.33
| Current Ratio | 5.33 |
| Quick Ratio | 5.07 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -5.81 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -49.24% |
| Return on Invested Capital (ROIC) | -107.67% |
| Return on Capital Employed (ROCE) | -73.64% |
| Revenue Per Employee | $399,104 |
| Profits Per Employee | -$963,601 |
| Employee Count | 556 |
| Asset Turnover | 0.30 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, BBIO has paid $1.15 million in taxes.
| Income Tax | 1.15M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +2.50% in the last 52 weeks. The beta is 1.07, so BBIO's price volatility has been similar to the market average.
| Beta (5Y) | 1.07 |
| 52-Week Price Change | +2.50% |
| 50-Day Moving Average | 31.67 |
| 200-Day Moving Average | 27.64 |
| Relative Strength Index (RSI) | 63.77 |
| Average Volume (20 Days) | 2,794,598 |
Short Selling Information
The latest short interest is 18.78 million, so 9.94% of the outstanding shares have been sold short.
| Short Interest | 18.78M |
| Short Previous Month | 20.38M |
| Short % of Shares Out | 9.94% |
| Short % of Float | 14.23% |
| Short Ratio (days to cover) | 6.67 |
Income Statement
In the last 12 months, BBIO had revenue of $221.90 million and -$535.76 million in losses. Loss per share was -$2.88.
| Revenue | 221.90M |
| Gross Profit | 221.90M |
| Operating Income | -577.37M |
| Pretax Income | -453.82M |
| Net Income | -535.76M |
| EBITDA | -571.29M |
| EBIT | -577.37M |
| Loss Per Share | -$2.88 |
Full Income StatementBalance Sheet
The company has $681.10 million in cash and $1.73 billion in debt, giving a net cash position of -$1.05 billion or -$5.55 per share.
| Cash & Cash Equivalents | 681.10M |
| Total Debt | 1.73B |
| Net Cash | -1.05B |
| Net Cash Per Share | -$5.55 |
| Equity (Book Value) | -1.46B |
| Book Value Per Share | -7.75 |
| Working Capital | 585.40M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$520.73 million and capital expenditures -$933,000, giving a free cash flow of -$521.66 million.
| Operating Cash Flow | -520.73M |
| Capital Expenditures | -933,000 |
| Free Cash Flow | -521.66M |
| FCF Per Share | -$2.76 |
Full Cash Flow StatementMargins
Gross margin is 100.00%, with operating and profit margins of -260.19% and -241.44%.
| Gross Margin | 100.00% |
| Operating Margin | -260.19% |
| Pretax Margin | -244.34% |
| Profit Margin | -241.44% |
| EBITDA Margin | -257.45% |
| EBIT Margin | -260.19% |
| FCF Margin | n/a |